Haemoglobin

Nephrology

Volumn 13, Issue SUPPL. 2, 2008, Pages

  McMahon, Lawrence ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM; CYANOCOBALAMIN; ERYTHROPOIETIN; FOLIC ACID; HEMOGLOBIN; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ALUMINUM OVERLOAD; ANEMIA; BLOOD PRESSURE REGULATION; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COCHRANE LIBRARY; DRUG INDICATION; DRUG USE; EXERCISE; HEMOGLOBIN DETERMINATION; HUMAN; HYPERPARATHYROIDISM; INFLAMMATION; MEDLINE; MESH HEADING; MORBIDITY; MORTALITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW;

EID: 47749103419     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2008.00997.x     Document Type: Review

References (48)

1. McMahon LP, Johns JA, McKenzie A et al. Haemodynamic changes and physical performance at comparative levels of haemoglobin after long-term treatment with recombinant erythropoietin. Nephrol Dial Transplant 1992 7 : 1199 206.
2. th Annual Meeting, ASN; 1993 Nov 14-17; Boston, USA: 425 (abstract).
3. Jacobs C. Normalization of haemoglobin: why not? Chairman's Workshop Report. Nephrol Dial Transplant 1999 14 (Suppl 2 S75 S79.
4. Benz RL, Pressman MR, Hovick ET et al. A preliminary study of the effects of correction of anemia with recombinant human erythropoietin therapy on sleep, sleep disorders and daytime sleepiness in hemodialysis patients (The SLEEPO Study). Am J Kidney Dis 1999 34 : 1089 95.
5. McMahon LP, McKenna MJ, Sangkabutra T et al. Physical performance and associated electrolyte changes after haemoglobin normalization: a comparative study in haemodialysis patients. Nephrol Dial Transplant 1999 14 : 1182 7.
6. McMahon LP, Mason K, Skinner SL et al. Effects of haemoglobin normalization on quality of life and cardiovascular parameters in end-stage renal failure. Nephrol Dial Transplant 2000 15 : 1425 30.
7. Besarab A, Bolton WK, Browne JK et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998 339 : 584 90.
8. Drueke TB, Locatelli F, Clyne N et al. for the CREATE Investigators. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006 355 : 2071 84.
9. Singh AK, Szczech L, Tang KL et al. for the CHOIR Investigators. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006 355 : 2085 98.
10. Parfrey PS, Foley RN, Wittreich BH et al. Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J Am Soc Nephrol 2005 16 : 2180 9.
11. Roger SD, McMahon LP, Clarkson A et al. Effects of early and late intervention with epoetin alpha on left ventricular mass among patients with chronic kidney disease (stage 3 or 4): results of a randomized clinical trial. J Am Soc Nephrol 2004 15 : 148 56.
12. Furuland H, Linde T, Ahlmen J et al. A randomized controlled trial of haemoglobin normalization with epoetin alfa in pre-dialysis and dialysis patients. Nephrol Dial Transplant 2003 18 : 353 61.
13. Phrommintikul A, Haas SJ, Elsik M et al. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet 2007 369 : 381 8.
14. Muirhead N. Erythropoietin is a cause of access thrombosis. Semin Dial 1993 6 : 184 8.
15. Churchill DN, Muirhead N, Goldstein M et al. Probability of thrombosis of vascular access among hemodialysis patients treated with recombinant human erythropoietin. J Am Soc Nephrol 1994 4 : 1809 13.
16. Lai KN, Lui SF, Leung JC et al. Effect of subcutaneous and intraperitoneal administration of recombinant human erythropoietin on blood pressure and vasoactive hormones in patients on continuous ambulatory peritoneal dialysis. Nephron 1991 57 : 394 400.
17. Canadian Erythropoietin Study Group. Effect of recombinant human erythropoietin therapy on blood pressure in hemodialysis patients. Am J Nephrol 1991 11 : 23 6.
18. Pollok M, Bommer J, Gurland HJ et al. Effect of recombinant human erythropoietin treatment in end-stage renal failure patients. Results of a multicenter phase II/III study. Contrib Nephrol 1989 76 : 201 11.
19. Shinaberger JH, Miller JH, Gardner PW. Erythropoietin alert: risks of high hematocrit hemodialysis. ASAIO Trans 1988 34 : 179 84.
20. Raine AE. Hypertension, blood viscosity, and cardiovascular morbidity in renal failure: implications of erythropoietin therapy. Lancet 1988 1 : 97 100.
21. Junor BJ. Hematocrit above 30% in continuous ambulatory peritoneal dialysis patients treated with erythropoietin is harmful. Perit Dial Int 1993 13 (Suppl 2 S535 S537.
22. Boobes Y. Pre-dialysis or post-dialysis hematocrit to monitor EPO treatment? Nephrology [abstract] 1997 3 (Suppl 1 S306.
23. Laudat K, Paulitschke M, Riedel E et al. Complete correction of renal anemia - no increased risk in access thrombosis or thromboembolic events in hemodialysis patients. J Am Soc Nephrol [abstract] 1998 9 : 219A.
24. Strippoli GF, Manno C, Schena FP et al. Haemoglobin and haematocrit targets for the anaemia of chronic renal disease. Cochrane Database Syst Rev 2003 1): CD003967.
25. Kleinman KS, Schweitzer SU, Perdue ST et al. The use of recombinant human erythropoietin in the correction of anemia in predialysis patients and its effect on renal function: a double-blind, placebo-controlled trial. Am J Kidney Dis 1989 14 : 486 95.
26. Lim VS, De Gowin RL, Zavala D et al. Recombinant human erythropoietin treatment in pre-dialysis patients. A double-blind placebo-controlled trial. Ann Intern Med 1989 110 : 108 14.
27. Bahlmann J, Schoter KH, Scigalla P et al. Morbidity and mortality in hemodialysis patients with and without erythropoietin treatment: a controlled study. Contrib Nephrol 1991 88 : 90 106.
28. Teehan BP, Benz RL, Sigler MH et al. Early intervention with recombinant human erythropoietin therapy. Semin Nephrol 1990 2 Suppl 1 S28 S34.
29. Clyne N, Jogestrand T. Effect of erythropoietin treatment on physical exercise capacity and on renal function in predialytic uremic patients. Nephron 1992 60 : 390 6.
30. Painter P, Moore G, Carlson L et al. Effects of exercise training plus normalization of hematocrit on exercise capacity and health-related quality of life. Am J Kidney Dis 2002 39 : 257 65.
31. Foley RN, Parfrey PS, Harnett JD et al. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int 1995 47 : 186 92.
32. Foley RN, Parfrey PS, Harnett JD et al. The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am J Kidney Dis 1996 28 : 53 61.
33. Levin A, Singer J, Thompson CR et al. Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention. Am J Kidney Dis 1996 27 : 347 54.
34. Collins AJ, Ma JZ, Xia A et al. Trends in anemia treatment with erythropoietin usage and patient outcomes. Am J Kidney Dis 1998 32 (6 Suppl 4 S133 S141.
35. Ma JZ, Ebben J, Xia H et al. Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol 1999 10 : 610 19.
36. Madore F, Lowrie EG, Brugnara C et al. Anemia in hemodialysis patients: variables affecting this outcome predictor. J Am Soc Nephrol 1997 8 : 1921 9.
37. Xia H, Ebben J, Ma JZ et al. Hematocrit levels and hospitalization risks in hemodialysis patients. J Am Soc Nephrol 1999 10 : 1309 16.
38. Locatelli F, Conte F, Marcelli D. The impact of haematocrit levels and erythropoietin treatment on overall and cardiovascular mortality and morbidity - the experience of the Lombardy Dialysis Registry. Nephrol Dial Transplant 1998 13 : 1642 4.
39. Berns JS, Rudnick MR, Cohen RM et al. Effects of normal hematocrit on ambulatory blood pressure in epoetin-treated hemodialysis patients with cardiac disease. Kidney Int 1999 56 : 253 60.
40. Brandt JR, Avner ED, Hickman RO et al. Safety and efficacy of erythropoietin in children with chronic renal failure. Pediatr Nephrol 1999 13 : 143 7.
41. Conlon PJ, Kovalik E, Shumm D et al. Normalization of hematocrit in hemodialysis patients does not affect silent ischemia. Renal Failure 2000 22 : 205 11.
42. Foley RN, Parfrey PS, Morgan J et al. Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int 2000 58 : 1325 35.
43. Abraham PA, Macres MG. Blood pressure in hemodialysis patients during amelioration of anemia with erythropoietin [abstract]. J Am Soc Nephrol 1991 2 : 927 36.
44. Kuriyama S, Tomonari H, Yoshida H et al. Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron 1997 77 : 176 85.
45. Morris KP, Sharp J, Watson S et al. Non-cardiac benefits of human recombinant erythropoietin in endstage renal failure and anaemia. Arch Dis Child 1993 69 : 580 6.
46. Revicki DA, Brown RE, Feeny DH et al. Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients. Am J Kidney Dis 1995 25 : 548 54.
47. Sikole A, Polenakovic M, Spirovska V et al. Analysis of heart morphology and function following erythropoietin treatment of anemic dialysis patients. Artif Organs 1993 17 : 977 84.
48. Watson AJ, Gimenez LF, Cotton S et al. Treatment of the anemia of chronic renal failure with subcutaneous recombinant human erythropoietin. Am J Med 1990 89 : 432 35.